Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Jul;21(7):261-3.
doi: 10.1038/cgt.2014.31.

Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land

Z S Guo  1 , D L Bartlett  1
Affiliations
Editorial

Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land

Z S Guo et al. Cancer Gene Ther. 2014 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Combination therapy with OV may enhance the overall therapeutic efficacy through multimodal modality mechanisms. Some chemotherapeutic drugs, radiation, photodynamic therapy (PDT) lead to direct cytotoxicity, and induce immunogenic cancer cell death (ICD), leading to danger signals (DAMPs) and TAAs to dendritic cells and thus further potentiates the antitumor immunity co-initiated by OV-mediated therapy. In addition, a number of therapeutics as well as OVT have been shown to be anti-angiogenic, which further induces massive cancer cell death. As a result, combinatorial therapies with OVs lead to enhanced efficacy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer. 2013;12:103. - PMC - PubMed
    1. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:74. - PMC - PubMed
    1. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2:295–300. - PMC - PubMed
    1. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther. 2010;18:251–263. - PMC - PubMed
    1. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol. 1998;16:444–448. - PubMed

Publication types

-